---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-25-000065"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2025-07-09T23:59:59+00:00"
generated_at: "2026-05-18T08:54:04.026862+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech doses first patient in Phase 1/2 trial of KB801 for neurotrophic keratitis

## Summary
- First patient dosed in Phase 1/2 EMERALD-1 trial of KB801, a redosable eye-drop gene therapy for neurotrophic keratitis.
- Study enrolls up to 27 adults with Stage 2 or 3 NK; 2:1 randomized to KB801 or placebo twice weekly for 8 weeks.
- Primary endpoint: safety/tolerability; secondary: complete durable corneal healing at week 8.
- NK diagnosed claims in US rose 115% from ~31,000 (2020) to ~68,000 (2024), per claims data.
- Investor call/webcast July 9 at 8:30am ET to discuss KB801 program and trial design.

## SEC filing metadata
- accession: 0001711279-25-000065
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2025-07-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000065/0001711279-25-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000065/krys-20250709.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-25-000065
- JSON: https://secwatch.observer/filing/0001711279-25-000065.json
- Plain text: https://secwatch.observer/filing/0001711279-25-000065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.